Why the study?
The effects of intravenous alteplase in patients with prior antiplatelet therapy remain controversial, particularly in unknown onset stroke.
Does intravenous alteplase improve functional outcomes in patients with unknown onset stroke regardless of prior antiplatelet therapy?
Does intravenous alteplase improve functional outcomes in patients with unknown onset stroke regardless of prior antiplatelet therapy?
Intravenous alteplase demonstrates consistent efficacy in unknown onset stroke regardless of prior antiplatelet therapy, without significantly increasing the risk of symptomatic intracranial hemorrhage or mortality.
Answers are grounded in this paper and cite their sources.
Supports alteplase in unknown-onset stroke with prior APT; confirms consistent efficacy without excess harm in this subgroup.
BACKGROUND: The effects of intravenous alteplase in patients with prior antiplatelet therapy (APT) remain controversial. We aimed to assess the efficacy and safety of imaging-based intravenous alteplase in patients with unknown onset stroke with prior APT. METHODS: Data from randomized controlled trials comparing alteplase with placebo/standard care in patients with unknown onset acute ischemic stroke from the Evaluation of Unknown Onset Stroke Thrombolysis (EOS) individual patient data meta-analysis collaboration were analyzed. Favorable outcome was defined as a modified Rankin Scale score of 0-1 at 90 days post-stroke. Safety outcomes included symptomatic intracranial hemorrhage (sICH) at 22-36 h and 90-day mortality. RESULTS: Overall, 780 patients had available baseline data on prior APT. Compared with the no prior APT group (n = 523), the prior APT group (n = 257) was older (72 vs. 66 years) and had a higher prevalence of vascular risk factors. There was no interaction between prior APT and treatment effects of alteplase (p for interaction = 0.23). In the prior APT patients, 55/125 (45%) patients in the alteplase group and 39/132 (30%) patients in the control group had a favorable outcome (adjusted odds ratio [aOR], 2.07 [95% confidence interval, 1.18-3.64]). The rates of sICH and mortality in the alteplase and control groups were 5.6% and 0.8% (aOR, 7.78 [0.94-63.37]) and 6.5% and 6.1% (aOR, 1.12 [0.38-3.36]), respectively. In the no prior APT patients, 136 patients (50%) in the alteplase group and 112 patients (45%) in the control group had a favorable outcome (aOR, 1.39 [0.94-2.05]). Safety outcomes were not significantly different between the groups (sICH: 3 [1.1%] vs. 1 [0.4%]; mortality: 13 [4.9%] vs. 3 [1.2%]). CONCLUSIONS: Alteplase has consistent efficacy regardless of prior APT in patients with unknown onset stroke. In addition, prior APT does not significantly increase the risk of sICH or mortality.
No takes yet. Share an insight, caveat, or question.
Shiomi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: